company
NOVARTIS
Jurisdiction: US
FDA Warning Letter timeline
V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.
- fda_approval · anda2026-07-01SANDOZ — ANDA approval: LIRAGLUTIDE (unspecified)
- fda_approval · nda2026-07-01NOVARTIS — NDA approval: KISQALI (unspecified)
- fda_approval · nda2026-07-01NOVARTIS — NDA approval: KISQALI FEMARA CO-PACK (COPACKAGED) (unspecified)
- fda_recall · drug_recall2026-06-24Sandoz Inc — Class III recall: Focalin XR (dexmethylphenidate HCl) 5 mg, 30 extended-release capsules per bottl…
Frequently asked questions
- How many FDA warning letters has NOVARTIS received?
- Argus HQ has not recorded an FDA warning letter for NOVARTIS in our current dataset.
- What FDA recalls has NOVARTIS issued?
- Argus HQ has recorded 1 FDA recall tied to NOVARTIS.
- Is NOVARTIS FDA compliant?
- Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 0 warning letters, 1 recall, and 3 approval records for NOVARTIS. Review the linked FDA source records directly before drawing a compliance conclusion.
Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.

